<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">JRSM Open</journal-id><journal-id journal-id-type="iso-abbrev">JRSM Open</journal-id><journal-id journal-id-type="publisher-id">SHR</journal-id><journal-id journal-id-type="hwp">spshr</journal-id><journal-title-group><journal-title>JRSM Open</journal-title></journal-title-group><issn pub-type="epub">2054-2704</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage UK: London, England</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25057363</article-id><article-id pub-id-type="pmc">4012680</article-id><article-id pub-id-type="doi">10.1177/2042533313509263</article-id><article-id pub-id-type="publisher-id">10.1177_2042533313509263</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Letter</subject></subj-group></article-categories><title-group><article-title>A randomised controlled trial of topical Kanuka honey for the treatment of eczema</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Fingleton</surname><given-names>James</given-names></name><xref ref-type="aff" rid="aff1-2042533313509263">1</xref><xref ref-type="corresp" rid="corresp1-2042533313509263"/></contrib><contrib contrib-type="author"><name><surname>Helm</surname><given-names>Colin</given-names></name><xref ref-type="aff" rid="aff2-2042533313509263">2</xref></contrib><contrib contrib-type="author"><name><surname>Tofield</surname><given-names>Chris</given-names></name><xref ref-type="aff" rid="aff2-2042533313509263">2</xref></contrib><contrib contrib-type="author"><name><surname>Weatherall</surname><given-names>Mark</given-names></name><xref ref-type="aff" rid="aff3-2042533313509263">3</xref></contrib><contrib contrib-type="author"><name><surname>Beasley</surname><given-names>Richard</given-names></name><xref ref-type="aff" rid="aff1-2042533313509263">1</xref><xref ref-type="aff" rid="aff3-2042533313509263">3</xref></contrib></contrib-group><aff id="aff1-2042533313509263"><label>1</label>Medical Research Institute of New Zealand, Wellington 6242, New Zealand</aff><aff id="aff2-2042533313509263"><label>2</label>Clinical Horizons, Tauranga 3112, New Zealand</aff><aff id="aff3-2042533313509263"><label>3</label>School of Medicine &#x00026; Health Sciences, University of Otago, Wellington 6242, New Zealand</aff><author-notes><corresp id="corresp1-2042533313509263">James Fingleton. Email: <email>james.fingleton@mrinz.ac.nz</email></corresp></author-notes><pub-date pub-type="epub"><day>7</day><month>1</month><year>2014</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2014</year></pub-date><volume>5</volume><issue>1</issue><elocation-id>2042533313509263</elocation-id><permissions><copyright-statement>&#x000a9; The Author(s) 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement><copyright-year>2014</copyright-year><copyright-holder content-type="society">The Royal Society of Medicine</copyright-holder><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (<ext-link ext-link-type="uri" xlink:href="http://www.creativecommons.org/licenses/by-nc/3.0/">http://www.creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page(<ext-link ext-link-type="uri" xlink:href="http://www.uk.sagepub.com/aboutus/openaccess.htm">http://www.uk.sagepub.com/aboutus/openaccess.htm</ext-link>).</license-p></license></permissions></article-meta></front><body><sec id="sec1-2042533313509263"><title>Objectives</title><p>Topical honey has been suggested to be effective in the treatment of eczema but there are no clinical trials as a single agent. One study reported use of honey, beeswax and olive oil mixture alone and in combination with topical steroids, and suggested that this mixture may be effective for the treatment of atopic dermatitis and psoriasis.<sup><xref rid="bibr1-2042533313509263" ref-type="bibr">1</xref></sup> We report a pilot study of the acceptability and feasibility of topical medical-grade Kanuka honey for the treatment of eczema.</p></sec><sec id="sec2-2042533313509263"><title>Design</title><p>An open-label single-blind randomized controlled trial was conducted. Participants applied medical-grade honey to a representative lesion on one side and aqueous cream BP to the other, every night for 2 weeks. Lesions were covered with a dry non-adherent dressing overnight. Choice of side was randomized by coin toss.</p></sec><sec id="sec3-2042533313509263"><title>Setting</title><p>Two primary care practices in Tauranga, New Zealand.</p></sec><sec id="sec4-2042533313509263"><title>Participants</title><p>There were 15 adult participants with a doctor&#x02019;s diagnosis of eczema involving the limbs, with bilateral lesions to allow comparison between treatments. Exclusion criteria were any corticosteroid use, requirement for antibiotic treatment or allergy to honey.</p></sec><sec id="sec5-2042533313509263"><title>Main outcome measures</title><p>Primary outcome measure was the lesion component of the validated SCORing Atopic Dermatitis measure,<sup><xref rid="bibr2-2042533313509263" ref-type="bibr">2</xref>,<xref rid="bibr3-2042533313509263" ref-type="bibr">3</xref></sup> assessed by a second investigator blinded to treatment allocation. Secondary outcome measures were Three Item Severity (TIS) score<sup><xref rid="bibr3-2042533313509263" ref-type="bibr">3</xref></sup> measured by the blinded investigator, unblinded measures were participant rated itch severity and acceptability of honey therapy, both measured by visual analogue score. The study was approved by the Multi-Region Ethics Committee of New Zealand (NZ), MEC-11-12-098, and written informed consent was obtained from all participants. One sample <italic>t-</italic>tests were used to estimate the difference between sides administered honey or control. An exact binomial method was used to calculate the confidence interval for the proportion of those with an adverse event. The sample size of 15 was chosen on the basis of variance estimation rather than to detect clinically important differences.</p></sec><sec sec-type="results" id="sec6-2042533313509263"><title>Results</title><p>The majority of subjects were women (8/15) and all subjects were included in the analysis, mean (SD) age 37.1 (12.1). Acceptability of honey therapy was moderate with mean duration of application over 8 hours, results shown in <xref ref-type="table" rid="table1-2042533313509263">Table 1</xref>. Mean (95% confidence interval) eczema severity was similar in honey and control groups at baseline, honey minus control &#x02212;0.5 (&#x02212;2.2 to 1.3). After 2 weeks, treatment change in lesion intensity was not different between groups, &#x02212;0.1 (&#x02212;1.5 to 1.4). TIS and subjective itch scores were also similar for honey and control, &#x02212;0.1 (&#x02212;0.9 to 0.6) and &#x02212;7.3 (&#x02212;27.7 to 13.2), respectively. One participant reported increased itch with honey application.
<table-wrap id="table1-2042533313509263" position="float"><label>Table 1.</label><caption><p>Comparison of 2 weeks' treatment with honey versus aqueous cream in eczema.</p></caption><table frame="hsides" rules="groups"><thead align="left"><tr><th rowspan="1" colspan="1">Honey</th><th rowspan="1" colspan="1">Aqueous cream</th><th rowspan="1" colspan="1">Honey minus cream<xref ref-type="table-fn" rid="table-fn7-2042533313509263">*</xref></th><th rowspan="1" colspan="1"><italic>P</italic> value&#x02020;</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><italic>Acceptability</italic></td></tr><tr><td rowspan="1" colspan="1">Score (0&#x02013;100)</td><td rowspan="1" colspan="1">60.6 (26.6)</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1"><italic>Clinical outcomes</italic></td></tr><tr><td rowspan="1" colspan="1">SCORAD lesion (0&#x02013;18)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;V1</td><td rowspan="1" colspan="1">4.6 (3.4)</td><td rowspan="1" colspan="1">5 (3.0)</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">&#x02003;V2</td><td rowspan="1" colspan="1">4.4 (1.3)</td><td rowspan="1" colspan="1">4.9 (3.5)</td><td rowspan="1" colspan="1">&#x02212;0.5 (&#x02212;2.2 to 1.3)</td><td rowspan="1" colspan="1">0.58</td></tr><tr><td rowspan="1" colspan="1">Change with treatment</td><td rowspan="1" colspan="1">&#x02212;0.2 (2.2)</td><td rowspan="1" colspan="1">&#x02212;0.1 (2.5)</td><td rowspan="1" colspan="1">&#x02212;0.1 (&#x02212;1.5 to 1.4)</td><td rowspan="1" colspan="1">0.92</td></tr><tr><td rowspan="1" colspan="1">TIS (0&#x02013;9)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;V1</td><td rowspan="1" colspan="1">1.9 (1.8)</td><td rowspan="1" colspan="1">1.9 (1.5)</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">&#x02003;V2</td><td rowspan="1" colspan="1">2.0 (2.1)</td><td rowspan="1" colspan="1">2.2 (1.9)</td><td rowspan="1" colspan="1">&#x02212;0.1 (&#x02212;1.0 to 0.8)</td><td rowspan="1" colspan="1">0.76</td></tr><tr><td rowspan="1" colspan="1">Change with treatment</td><td rowspan="1" colspan="1">0.1 (1.4)</td><td rowspan="1" colspan="1">0.3 (1.4)</td><td rowspan="1" colspan="1">&#x02212;0.1 (&#x02212;0.9 to 0.6)</td><td rowspan="1" colspan="1">0.70</td></tr><tr><td rowspan="1" colspan="1">Itch (0&#x02013;100)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;V1</td><td rowspan="1" colspan="1">41.7 (27.6)</td><td rowspan="1" colspan="1">41.2 (21.9)</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td></tr><tr><td rowspan="1" colspan="1">&#x02003;V2</td><td rowspan="1" colspan="1">26.4 (30.5)</td><td rowspan="1" colspan="1">33.1 (24.5)</td><td rowspan="1" colspan="1">&#x02212;6.7 (&#x02212;26.1 to 12.7)</td><td rowspan="1" colspan="1">0.47</td></tr><tr><td rowspan="1" colspan="1">Change with treatment</td><td rowspan="1" colspan="1">&#x02212;15.3 (36.4)</td><td rowspan="1" colspan="1">&#x02212;8.0 (31.9)</td><td rowspan="1" colspan="1">&#x02212;7.3 (&#x02212;27.7 to 13.2)</td><td rowspan="1" colspan="1">0.46</td></tr><tr><td rowspan="1" colspan="1"><italic>Adherence</italic></td></tr><tr><td rowspan="1" colspan="1">Duration of use (min)</td><td rowspan="1" colspan="1">503 (99.3)</td><td rowspan="1" colspan="1">502 (98.2)</td><td rowspan="1" colspan="1">&#x02013;</td><td rowspan="1" colspan="1">&#x02013;</td></tr></tbody></table><table-wrap-foot><fn id="table-fn1-2042533313509263"><p>Values reported as mean (SD) unless otherwise stated.</p></fn><fn id="table-fn2-2042533313509263"><p>For SCORAD (SCORing Atopic Dermatitis) lesion and Three Item Severity (TIS scores), higher scores represent more severe disease.</p></fn><fn id="table-fn3-2042533313509263"><p>Acceptability scores range from 0 &#x02018;Completely unacceptable&#x02019; to 100 &#x02018;Completely acceptable&#x02019;.</p></fn><fn id="table-fn4-2042533313509263"><p>Itch scores range from 0 &#x02018;No itch&#x02019; to 100 &#x02018;Worst itch possible&#x02019;</p></fn><fn id="table-fn5-2042533313509263"><p>V1: Baseline visit 1.</p></fn><fn id="table-fn6-2042533313509263"><p>V2: Visit 2 after 2 weeks&#x02019; treatment.</p></fn><fn id="table-fn7-2042533313509263"><label>*</label><p>Mean (95% confidence interval).</p></fn><fn id="table-fn8-2042533313509263"><label>&#x02020;</label><p>One sample <italic>t</italic>-test.</p></fn></table-wrap-foot></table-wrap></p></sec><sec sec-type="conclusions" id="sec7-2042533313509263"><title>Conclusions</title><p>In this pilot single-blind randomized controlled trial of topical medical-grade Kanuka honey for the treatment of eczema, Kanuka honey treatment was found to be feasible with moderate acceptability. There was no evidence of efficacy above that of the aqueous cream control. Aqueous cream is not recommended as a treatment in eczema and represents a negative control.<sup><xref rid="bibr4-2042533313509263" ref-type="bibr">4</xref></sup> Important limitations of this study are the small sample size, which means that we cannot rule out a small but clinically important response to topical honey, and incomplete blinding due to the physical characteristics of honey.</p><p>Topical application of medical-grade Kanuka honey does not appear to be effective in the management of eczema.</p></sec></body><back><sec id="sec8-2042533313509263"><title>Declarations</title><sec id="sec9-2042533313509263"><title>Competing interests</title><p>Shaun Holt, the Medical Director of Honeylab, was previously the Programme Director of Complementary Medicine at the Medical Research Institute of New Zealand. The authors have no other competing interest to declare.</p></sec><sec id="sec10-2042533313509263"><title>Funding</title><p>The study was sponsored by Honeylab, a manufacturer of medical-grade Kanuka honey. The Sponsor had no role in the design, conduct and analysis of the study or the decision to publish.</p></sec><sec id="sec11-2042533313509263"><title>Ethical approval</title><p>The study was approved by the Multi-Region Ethics Committee of New Zealand (NZ), MEC-11-12-098, and written informed consent was obtained from all participants.</p></sec><sec id="sec12-2042533313509263"><title>Guarantor</title><p>JF</p></sec><sec id="sec13-2042533313509263"><title>Contributorship</title><p>JF, MW and RB designed the study with input from CH and CT. JF, CH and CT conducted the study with analysis performed by MW, JF and RB. JF wrote the first draft and all authors revised and approved the final manuscript.</p></sec><sec id="sec14-2042533313509263"><title>Acknowledgements</title><p>None</p></sec><sec id="sec15-2042533313509263"><title>Provenance</title><p>Not commissioned; peer reviewed by George Lewith</p></sec></sec><ref-list><title>References</title><ref id="bibr1-2042533313509263"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Waili</surname><given-names>NS</given-names></name></person-group>
<article-title>Topical application of natural honey, beeswax and olive oil mixture for atopic dermatitis or psoriasis: partially controlled, single-blinded study</article-title>. <source>Complement Ther Med</source>
<year>2003</year>; <volume>11</volume>(<issue>4</issue>): <fpage>226</fpage>&#x02013;<lpage>234</lpage><pub-id pub-id-type="pmid">15022655</pub-id></mixed-citation></ref><ref id="bibr2-2042533313509263"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmitt</surname><given-names>J</given-names></name><name><surname>Langan</surname><given-names>S</given-names></name><name><surname>Williams</surname><given-names>HC</given-names></name></person-group>
<article-title>What are the best outcome measurements for atopic eczema? A systematic review</article-title>. <source>J Allergy Clin Immunol</source>
<year>2007</year>; <volume>120</volume>(<issue>6</issue>): <fpage>1389</fpage>&#x02013;<lpage>1398</lpage><pub-id pub-id-type="pmid">17910890</pub-id></mixed-citation></ref><ref id="bibr3-2042533313509263"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oranje</surname><given-names>AP</given-names></name></person-group>
<article-title>Practical issues on interpretation of scoring atopic dermatitis: SCORAD Index, objective SCORAD, patient-oriented SCORAD and Three-Item Severity score</article-title>. <source>Curr Probl Dermatol</source>
<year>2011</year>; <volume>41</volume>: <fpage>149</fpage>&#x02013;<lpage>155</lpage><pub-id pub-id-type="pmid">21576955</pub-id></mixed-citation></ref><ref id="bibr4-2042533313509263"><label>4</label><mixed-citation publication-type="other"><comment>National Collaborating Centre for Women&#x02019;s and Children&#x02019;s Health. Atopic eczema in children RCOG Press. See <ext-link ext-link-type="uri" xlink:href="http://guidance.nice.org.uk/CG57/Guidance/pdf/English">http://guidance.nice.org.uk/CG57/Guidance/pdf/English</ext-link> (last checked 3 December 2013)</comment></mixed-citation></ref></ref-list></back></article>